Fat, Carbohydrate Quality Impact Postprandial Blood Glucose

This article originally appeared here.
Share this content:
Fat, Carbohydrate Quality Impact Postprandial Blood Glucose
Fat, Carbohydrate Quality Impact Postprandial Blood Glucose

FRIDAY, Feb. 12, 2016 (HealthDay News) -- For patients with type 1 diabetes, fat quality influences postprandial blood glucose (PPG) response in the context of meals with high-glycemic index (HGI), according to a study published online Feb. 9 in Diabetes Care.

Lutgarda Bozzetto, M.D., Ph.D., from Federico II University in Naples, Italy, and colleagues conducted a randomized crossover design study involving 13 patients with diabetes on insulin pump. Participants consumed two series of meals with the same carbohydrate quantity (HGI or low glycemic index [LGI]) and different quality fats: low in fat; high in saturated fat (butter); or high in monounsaturated fat (extra-virgin olive oil [EVOO]). Continuous glucose monitoring was performed and six-hour postprandial blood glucose was examined.

The researchers found that PPG differed significantly for HGI and LGI meals, and was significantly higher during the first three hours after the HGI meals, with a tendency toward the opposite pattern later. PPG was significantly lower after EVOO versus low-fat or butter in the context of HGI meals, with a marked difference seen in the zero- to three-hour glucose incremental area under the curve between EVOO and low-fat or butter (P < 0.05). In the context of the LGI meals, there were no significant differences in PPG.

"An optimal prandial insulin administration would require considering, in addition to the quantity of carbohydrates, the quality of both carbohydrate and fat," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »